NCT07573956RecruitingPhase 2/3
Trial Evaluating Hypo-fractionated Accelerated Versus Conventional Fractionated Adjuvant RT in Head & Neck Malignancies
The HYPCON 3 Trial A Phase II/III Randomized Study Evaluating Hypo-fractionated Accelerated Versus Conventional Fractionated Adjuvant Radiation Therapy in Head and Neck Malignancies
Source: ClinicalTrials.gov · Last updated 7 May 2026
Brief summary (registry, in English)
Hypo-fractionated radiotherapy reduces the OTT (overall treatment time) which may in turn reduce rapid accelerated repopulation of clonogenic cells during waiting period after surgery. If this holds true, there is a potential to achieve better loco-regional control in with PORT for HNSCC. There is a strong radiobiological and economic rationale for delivery hypo-fractionated radiotherapy in HNSCC. The HYPCON III trial will be aimed to reduce the number of fractions by 50% (30 fr to 15 fr)
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 369 (estimated)
- First submitted
- 28 Apr 2026
- Start date
- 10 Feb 2026
- Primary completion date
- 30 Jun 2028
- Lead sponsor
- All India Institute of Medical Sciences
- Diseases
- Head and neck cancer
- NCT number
- NCT07573956
What you commit to
- Study type: Interventional · Phase 2/3
- Planned participants: 369
- From 10 Feb 2026 to the primary completion date, 30 Jun 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- High risk factors following resection: positive-margin(s)and/or extra nodal extension (ENE)
- Patients receiving Neo-adjuvant or concurrent Chemotherapy
- Prior Radiotherapy to head and neck region
Other illness
- Synchronous or second primary malignancy outside of the oropharynx, oral cavity, larynx and hypopharynx
Other
- pT1-2disease and no high-risk features (LVSI, PNI, Close margins,pN0)
- Non-Squamous Histology
- Distant metastasis
- Pregnant females or nursing mothers due to the probability of congenital anomalies and potential of this regimen to harm nursing infants.
Who the study is looking for
- Patients with pT1-4 squamous cell carcinoma of oral cavity/ oropharynx/ larynx/ hypopharynx with any of the intermediate risk features:
- Positive lymph node (s)
- Perineural invasion
- Lympho-vascular invasion
- Close margins
- Age 18-80yrs
- ECOG performance status 0-1at time of surgery
- Informed consent
- Available FOR long term follow-up
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dr. Aman Sharma, Associate Professor, Radiation Oncology, NCI, AIIMS Coordinator of this site? Confirm its status | Jhajjar | India | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.